Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how exercise affects the health and well-being of adults who have finished treatment for cancer and are now being monitored to make sure the cancer doesn’t come back. Specifically, the study wants to understand if exercising after cancer treatment can improve outcomes related to cancer and overall health. Researchers will use past information collected from cancer survivors who have shared details about their exercise habits during follow-up visits at Memorial Sloan Kettering Cancer Center.

Adults aged 18 and older who have had invasive cancer and completed their main cancer treatments at least three months ago may be eligible to join. To qualify, participants must have filled out surveys about their exercise habits over time, showing they were not exercising much at first but then reported their current activity levels. They must also have no signs that their cancer has returned and not have certain health problems like severe heart or lung disease that would make exercising unsafe. Participants won’t need to start a new exercise program for the study; instead, researchers will look at their past and current exercise information to see how it relates to their health outcomes. This study aims to help doctors understand the role of physical activity in cancer recovery and long-term health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Target trial (ideal RCT)
• • Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).
• • Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \[i.e., reporting \<10 metabolic equivalent-hours per week (MET-h/week)\]. Patients completing an additional exercise survey between th and baseline are excluded.
• • No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment
• • Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.
• • Undergoing surveillance in the Cancer Survivorship Program at MSK
• • Emulation using observational data
• • Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.
• • Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).
• • Non-exercising (i.e., reporting \<5 MET-h/week) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).
• • Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.
• • No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.
• • Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.